NeOnc schedules FDA meeting for NEO212 Phase 2 design review
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) announced it is scheduled to meet with the U.S. Food and Drug Administration on ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)

